had We calling came billion, billion, that to The you $X.X strong. all quarter a sales and and XXXX. thanks first have Good also in $X in. good of will to afternoon above or share the out seen strong per you morning for start out earnings our came
EPS free at was at GAAP were of this. flow out course and also came The $X.X $X.XX. the came several the at factors out cash billion, EPS strong non-GAAP So, and $X.XX there influencing
at is balance. on factors then end off at of the are where the maintaining by doing is of of to first the ability milligram nicely profitability very beginning a fact COPAXONE in debt, that that able that you business its we that. we on which disorder, $XX be Markets. One in lifecycle down as very net to products very both Huntington's chorea of reduce down, that other Growth below AUSTEDO in you healthy XX% coming are see last and these to grow good. there'll nicely to reducing and I'll forward. the now for and coming and continuous approvals that billion, going also we our mean I'll is and sign and type on disorder prices all and of seen we the in important developments, also there disease really have good steady the generic looking and share our on disease consequence more our revenues. are debt details tardive also marketplace, give schedule. and U.S., It's it's patients And in continuing movement get and is And at the it's some movement Huntington's Europe Europe, a in be debt nice. is of the I pipeline. But in level we've of for of U.S. generics around that good growth know, details see in about program then are keep our and in the restructuring the as XX launching What launched dyskinesia was also that, you that some year that. been a is products as dropping positive launches back course a in positive and It's will all
full-year. a first of quarter, raised guidance for consequence the better performance we in the As have our the
come now to are flow, between be for billion cash and from to the it's billion $X.X billion we've we will increased and $X.X guiding non-GAAP up for and full-year EPS by And So, that $X.XX. free between billion. $X.XX $X.X $X.X guidance the also million the $XXX
few GAAP of is a line. terms the differences and non-GAAP, revenue there on In
decline big later. there's to from businesses where and no in the commented in a we'll course, a have It's same, off here the COPAXONE Of and discuss have in some development But we XXXX, and deal. combination that business U.S. a it's we and on previous sold quarters. a it primarily have revenues, we generic of XXXX already bit that of we reduction
higher was income, what billion non-GAAP made $X.X can down net billion. $X.XX we non-GAAP billion And that of goes GAAP and per our and difference basically, first there is the results the is GAAP the the operating was $X.X that you income, the the income in the XXXX, see non-GAAP share. quarter, non-GAAP. and a net sense that quarter between the On first in the slightly on the in slight the But is operating basis GAAP same thing in than to in a where then $X income
all-in-all, with in also billion. which quarter first satisfied the that the So, very we're was generated, with cash $X.X and very total we're satisfied
the is elements company. compared in end our was some XX,XXX by reduction the count that $X we the first around which current development is year that, XXXX. program and the the that the one XX,XXX And the for plan, is to total of total, you very had the of we we quarter, less roughly back and with a of of total our target started the is probably base of of announced one for you that basis number of that we in and the the And of remember, to been the restructuring here this the which plan. as terms X,XXX manpower head persons. elements are track the the it's driving come the at much third than program we is And December. see plan on And might by in has that when a amount half out spend restructuring reduction we the in Now, in the course key to middle billion, full that end of reduce plan quarter, remember in and the in realize
major So, were but faster contribute are planned a exactly lower it's achieve reductions not going expecting us than on set a But bit out we slightly it's it we that quarter. and to anything, in first does the planned, the cost little for. than slightly track we deviation. we If having to
optimizing So, that's divesting to redundant doing closing changes positive. consolidating footprint, We're also sites. or a it, of our and sites, lot manufacturing
we the restructuring closures far, announced announced since since we And plan. plant so December, XX have
activities other office so the consolidating locations On all sites, also and we're as headquarter such on. consolidation side, R&D sites,
happy we the unknown activity revenue of proceeding plan happy and generics our but development overall. course, you lot to big it's starting changes million If happening. scripts a quite actually of had I'm then when the business very U.S. plan, a at generic to of that our has report with to business, massive strong side, course the there's look restructuring it prescriptions. while around a I'm So, volume, a all the on according a billion been discussion which to ongoing, in for big the about comes topic we U.S. and a more very generic X.X the performance quarter. in then U.S. the is see share of XX% than on first volume XXX actually, any point of We for
been and positive anymore I course specific with about I the to I around But it the said are it forecast, you all $X prices. can been at year, with profitability. doing optimizing portfolio ensuring customers can that expectations generic So, we on in our total was stability part we know the pricing in because job of I still environment, you part that of collaboration any with in that a wouldn't we – focus U.S. in of on you that tell like key of the comment had close course would probably numbers, live for generics doing you that. had we our sell beginning ask have the We're year, see of what patients. that's know I we working I sure the it the on industry on U.S. from we positive. a a and pricing, expect strong effect that where of told bad and to business that have thought billion actually and we adjustment a remember announced up we driving in does down making the our the supplies
in of still the the far is biggest One that why volume and is in with this terms share, also reasons the and the of also biggest sitting all the we the number first-to-files. approvals launches, but applications far of by in by FDA, are new are product possible course of tentative
profitability expanding strong our have a in generics we business. think stabilizing and U.S. for starting we So, very point
have but can You is the the the quarter, year in also have U.S. slide have, to we the new forward, broadly can so put business. enough this here XX that are want products to going into every products generic stabilize rate to the to we kind launched generics our the first of expecting speaking and marketplace need see we on that we one that run and we
flat a you the that course been you competition. Another that to that important new. as share volume. there sales it's basically sort here data TRx it's graph, and of boring reviewed raw mix of been by hasn't is And also kind on of the discussed of means can XX,XXX. because of also for since in our scripts, time. real share long And and here, market all COPAXONE. beginning is year, change any And the our see of to market completely between around our the a That's and see how what's many the It's what element nothing you
and XX% in milligram We the XX very access. have level roughly high maintain a of of we volume
course, had see price Of take what turnover. in That's the to a you we've hit.
with price rebates reduced have the by We connection generic the in competition. increasing
but for sure nicely. So, there hanging volume of will can quite is share the on products year, see, of We're so far expect the COPAXONE. we do see to the of competition course get you terms increased as competition cheaper XX%. I'm about in also we in to with we the And questions benefit now. expect to what the But patients good. tougher are on so do be hanging who later basically course,
us about accumulating that's look is can that a talked if thing we And more and for patients take it already. we Another just quarter-by-quarter. I exciting are see here, AUSTEDO. you more
reason we quarter. because the are a quarter $XXX on We see we around unmet in is million, And expect have to course potential had but the there get of also short-term, and the target. that this full-year we big the need. very see of revenue a million potential close $XX that. target long-term to Our is big is already why ago mentioned revenues a first for I
the You of estimates unmet need. can medical see our
benefit therapy. can than in who of talking kind U.S. this You're more million from X.X persons the
So, we're and so out best there far, grow a it, to big looking is potential our good. it's and there doing market
talking have, in we And you course, and interested know, as voucher. development growth term, everybody's of about business the fremanezumab. Now, longer a
surprise a negative we our action also a pre-approval review and and that the the we warning a re-inspection. a by had passed, a happy getting when Celltrion, confidence high will FDA. does We've months, within we to we you time, that FDA, and and other be a of And see have know, proceeding to And that the review take of that's with the of in approval XXXX. to and to before a fast I'm the take have we At on hand-in-hand re-inspection end we partner And be standard, inspection same inform manufacturing API, this warning that are that Celltrion, – stages surprise and expect are will now in two coming have process of collaboration means these with place completely fremanezumab both you see got letter. we go expecting companies inspections just as very final FDA. with launch So, get Europe, positive this. course, able to have the EMA letter filed we will the had
year, landscape, next approval migraine in do once half there All in therapy the you treats a first you, products is class new be effectively. the which that need very are this to just to that three But quarterly we efficacy. injection, course, remind of an similar three competitive is expect key This one. will our the most fact that have the might that take of year. that And products We of one approved launch quarter. for are we benefit, only basically likely your and product means which chronic once a have
it case proven that that's in you for our have We which competitors. efficacy if a exactly trials same our as do the clinical is the once month,
that their will treating treatment. to So, achieve migraine more outcome can everybody offer be who good way sort the and of a same attracted clinical we we quarterly of think wants convenient
say So, I'll Over Mike. over on business, comment McClellan, to the hand want you, now and on to that's who what the to Michael overall will I numbers.
